Lineage Cell Therapeutics (LCTX) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to -$41.7 million.
- Lineage Cell Therapeutics' Enterprise Value fell 2236.46% to -$41.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$41.7 million, marking a year-over-year decrease of 2236.46%. This contributed to the annual value of -$49.2 million for FY2024, which is 3330.62% down from last year.
- According to the latest figures from Q3 2025, Lineage Cell Therapeutics' Enterprise Value is -$41.7 million, which was down 2236.46% from -$43.6 million recorded in Q2 2025.
- Over the past 5 years, Lineage Cell Therapeutics' Enterprise Value peaked at -$34.1 million during Q3 2024, and registered a low of -$98.5 million during Q4 2022.
- Its 5-year average for Enterprise Value is -$55.7 million, with a median of -$49.2 million in 2024.
- Its Enterprise Value has fluctuated over the past 5 years, first plummeted by 21753.64% in 2021, then surged by 6256.74% in 2023.
- Over the past 5 years, Lineage Cell Therapeutics' Enterprise Value (Quarter) stood at -$59.7 million in 2021, then tumbled by 65.12% to -$98.5 million in 2022, then skyrocketed by 62.57% to -$36.9 million in 2023, then crashed by 33.31% to -$49.2 million in 2024, then grew by 15.14% to -$41.7 million in 2025.
- Its last three reported values are -$41.7 million in Q3 2025, -$43.6 million for Q2 2025, and -$49.3 million during Q1 2025.